VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	10/11/2013 8:35:36 AM
	Read Replies (2) of 23519

A jump in Qsymia scripts or insurance reimbursement progress would have been nicer, but this seems to be helpful. Oct 11 (Reuters) - Vivus Inc's erectile dysfunction drug will be marketed by Auxilium Pharmaceuticals Inc in the United States and Canada in a deal worth up to $300 million, including an upfront licensing fee of $30 million. Auxilium said the deal would add to its earnings in 2015. Vivus, known for its diet pill Qsymia, will be responsible for the initial supply and manufacturing of the oral drug, Stendra, Auxilium said in a statement. The company said it expected to begin the commercial launch of the drug by the end of 2013 and start shipping the drug in December. Vivus said the deal would help it tap the established sales network of Auxilium, which markets men's health products such as testosterone gel, Testim. Stendra was approved by U.S. health regulators in April 2012.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next